Effect of empagliflozin on blood pressure, cardiovascular events, mortality and renal parameters

Evaluating the effect of empagliflozin on blood pressure, cardiovascular events, mortality and renal parameters in patients undergoing coronary artery bypass surgery admitted to the A coronary care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190911044744N3

Enrollment

Registered

2023-12-03

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing coronary artery bypass surgery. Unspecified complication of cardiac and vascular prosthetic device, implant and graft

Interventions

Intervention 1: Intervention group:Recipients of empagliflozin 10 mg tablets from Abidi Pharmaceutical Company receive one empagliflozin tablet orally a few hours after coronary artery bypass surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing coronary artery bypass surgery Not being allergic to empagliflozin

Exclusion criteria

Exclusion criteria: Patients who cannot get enough information with echocardiography History of taking pioglitazone at least 8 weeks before entering the study Glomerular filtration rate less than 30 mg per minute per 1.73 square meters of body surface based on the CKD-EPI formula Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Reduction of blood pressure. Timepoint: Daily. Method of measurement: Mercury pressure gauge.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Mirzaei

Yazd University of Medical Sciences

ehsan.mirzaei.1369@gmail.com+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026